Duvelisib is a potent, oral phosphatidylinositol 3-kinase (PI3K) inhibitor indicated for the treatment of patients with certain types of chronic lymphocytic leukemia and small lymphocytic lymphoma. As… Read more








Duvelisib is a potent, oral phosphatidylinositol 3-kinase (PI3K) inhibitor indicated for the treatment of patients with certain types of chronic lymphocytic leukemia and small lymphocytic lymphoma. As a therapeutic agent, it modulates critical signaling pathways involved in cell growth and survival. The analytical study of this drug requires high-quality reference standards, including the active pharmaceutical ingredient, to ensure accurate identification and quantification. Laboratories utilize these related compounds, such as degradation-related impurities like N-nitroso and ring-opened structures, as well as specific metabolites like N-glucuronide, to conduct rigorous impurity profiling. Additionally, stable isotope labelled compounds are essential for use as internal standards in mass spectrometry to enhance the precision of quantitative analysis during method validation and stability testing. Access to these characterized materials supports the comprehensive quality control protocols necessary for monitoring the development and manufacturing lifecycle of this kinase inhibitor.